Jorgen Winroth has joined Sobi to lead the company's Investor Relations activities. Jorgen has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. Jorgen has also served as a consultant providing strategic Investor Relations services to a number of Scandinavian corporations including Hafslund Nycomed AS, AB SKF, and Huhtamaki Oy, and previously as Vice President, Investor Relations at Pharmacia. Jorgen will be based in New York. Åsa Stenqvist, who has served as interim Head of Communications and Investor Relations, will leave Sobi on November 16. "We are very pleased to welcome Jorgen to Sobi. He brings extensive experience in Investor Relations and will focus on increasing our level of service and on building awareness of Sobi in the investment community. At the same time we want to thank Åsa for her many contributions to Sobi and wish her good luck in the future," says Geoffrey McDonough, CEO of Sobi. For further information, please contact: Åsa Stenqvist, Head of Communications and IR (Interim) at +46 8 697 21 88 or Jorgen Winroth at [email protected]. About Sobi Sobi is an international healthcare company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also markets more than 40 products for companies in the specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 10 October 2012 at 2:00 p.m. CET.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.